The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...
January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...
This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...
Addressing Neurologic Toxicities in CAR-T Therapy: Monitoring, Management, and Patient Communication
Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...
This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to ...
Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...
An expert discussion surrounding experience with managing weight gain and gastrointestinal adverse events associated with lorlatinib, addressing quality of life, symptom mitigation strategies, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback